49 results about "Bone gla protein" patented technology

The present invention relates to a method of producing osteocyte cell line in various stages of differentiation. Such cell line remains stable after more than 20 passages. The osteocyte has a stellate shape with dendritic processes and expresses high level of osteocalcin. More specifically, it provides a method of production for cultured osteocytes of various differentiation stages. Furthermore, it relates to osteocyte cell line, and more specifically cultured osteocyte. The invention also relates to a method for the production of monoclonal antibodies using such cultured osteocytes and further relates to hybridomas and monoclonal antibodies which recognize an osteocyte-specific antigen. Finally, the invention relates to a method of screening for modification factors and binding factors for osteocytes.

The invention relates to new use of taurochenodeoxycholic acid, in particular to the new use of the taurochenodeoxycholic acid in prevention and treatment of osteoporosis. Through the study on taurochenodeoxycholic acid, the inventor found that the taurochenodeoxycholic acid can promote bone cells to secrete osteocalcin and improve lowered bone density. Thus, the taurochenodeoxycholic acid can beused in prevention or treatment of osteoporosis. After being administrated directly or being formed into various formulations, the taurochenodeoxycholic acid can be used for preventing or treating osteoporosis and other related diseases or states of osteoporosis.

The invention discloses a kit using a magnetic particle chemiluminiscence method to measure osteocalcin (BGP) content. The kit comprises a calibration article, a quality control article, a resisting reagent, a magnetic particle reagent and a light-emitting substrate, wherein the resisting reagent comprises an antibody marked by fluorescein isothiocyanate and coated by osteocalcin and an antibody marked by alkaline phosphatase and osteocalcin; the magnetic particle reagent is used for connecting magnetic particles with anti-goat FITC. The kit has the advantages that the chemiluminiscence technology is combined with immune magnetic particles, a reaction system close to homogeneous phase is provided, a one-step reaction mode is used, the detection sensitivity and precision of the kit are increased greatly, the detection range of the kit is increased, reaction time is shortened greatly, time from sample feeding to a detecting result is less than 35 minutes, and the detection speed of the kit is evidently higher than that of similar kits; the kit can detect multiple samples at the same time on full-automatic chemiluminescence apparatus, high-throughput and fast measuring of the osteocalcin is achieved, the kit is high in accuracy and high in specificity, and the accuracy and detection efficiency of the kit are increased greatly.

The invention discloses a method for preparing bone calcium and bone gla protein prepared by means of the method. The method comprises the following steps of three-time defatting, two-time centrifugation, two-time fermentation and secondary protease hydrolysis. Fat in bone meal prepared by adopting a defatting process is completely removed basically, so that the fat content in calcium obtained by means of enzymolysis is lower than 0.1%. The bone gla protein is safe and healthy to consumers with cardiovascular disease, and economical burden to the consumers is not increased.

The invention discloses a method for extracting bone calcium by fermentation, and osteocalcin. The method comprises the steps of crushing the bone, fermenting lactic acid bacteria, heating for sterilization, enzymolizing, adding alkali to neutralize an enzymatic hydrolysate, inactivating and drying to obtain the osteocalcin. Compared with the osteocalcin prepared by a convention technology, the osteocalcin prepared by the enzymolysis technology has greatly increased free calcium content. The final prepared product has better balanced nutrition.

The invention discloses a bone calcium extraction method by double fermentation. The bone calcium extraction method by double fermentation includes the steps of fermenting before enzymolysis, enzymolysis and fermenting after enzymolysis. Free calcium content of bone gla protein made by the bone calcium extraction method compared with the prior art is increased greatly. The obtained bone gla protein has fine taste and fragrance, and peculiar odors in extract are removed.

The invention relates to a high-calcium protein food product, in particular to a high-calcium protein food product which is produced by using animal bones, fish bones or egg shells of bird species; the invention aims at a producing method of the high-calcium protein food product that fully uses resources of the animal bones, the fish bones or the egg shells of bird species and acid hydrolysis solution after carrying out acid hydrolysis by organic acid; the producing method comprises the following steps: the animal bones, the fish bones or the egg shells of bird species are adopted as raw materials, the organic acid executes acid hydrolysis, large grains are removed, auxiliary materials or additives are added to prepare the taste, and sterilization, concentration and drying are carried out, thus producing the high-calcium protein food product; the invention develops a new high-calcium protein food product so as to fully utilize the resources of the animal bones, the fish bones or the egg shells of poultry.

The invention discloses a bone calcium extraction method and osteocalcin prepared by the bone calcium. The extraction method comprises the steps of composite enzymatic hydrolysis and fermentation. Free calcium content in the osteocalcin prepared by the invention is increased by 5%-25% than that in the osteocalcin prepared by enzymatic hydrolysis with a conventional technology. The final prepared product has good mouthfeel and is aromatic; and the peculiar smell in the extract product is removed.

The invention discloses an animal bone calcium extraction method and bone gla protein made thereby. The animal bone calcium extraction method includes the steps of triple defatting, double centrifuging, fermenting, and compound protease hydrolysis. Fat in the bone powder made by the defatting process is substantially removed, so that fat content of calcium agent obtained by enzymolysis is smaller than 0.1%. The bone gla protein is safer and healthier for consumers with cardiovascular diseases but causes no increase in financial burden.

The invention discloses a chemiluminescent detection kit for N-middle osteocalcin and a preparation method thereof. The kit includes: magnetic particles coupled with N-terminal osteocalcin capture antibody, acridinium ester-labeled N-terminal osteocalcin detection antibody, N-terminal osteocalcin series standards, chemiluminescent pre- Excitation solution A, chemiluminescence excitation solution B, cleaning solution. The kit of the invention uses the magnetic separation chemiluminescence technology as the detection means, and simultaneously combines the acridinium ester labeling technology. Compared with the existing technology for detecting N-terminal osteocalcin, this kit has the advantages of high sensitivity, high signal-to-noise ratio and rapid detection.

The invention discloses a use of osteocalcin for preparing medicine for treating Parkinson's diseases. The effects that exogenous application of the osteocalcin can relieve the dyskinesia of a rat model with the Parkinson's diseases and can reduce the substantia nigra dopaminergic neuron loss, and the PC12 cell apoptosis caused by 6-OHDA can be reduced through AKT/GSK path in vitro. Therefore theosteocalcin as a small molecule polypeptide hormone capable of passing through blood brain barrier can become fire-new medicine for preventing and treating the occurrence and the development of the Parkinson's diseases.

Methods and devices are described for the regulation of BMP 2 and 4, TGF-beta 1, 2, and 3, FGF-2, osteocalcin, and alkaline phosphatase mRNA in stem cells via capacitive coupling or inductive coupling of specific and selective electric and/or electromagnetic fields to the bone cells or other tissues containing the stem cells, where the specific and selective fields are generated by application of specific and selective signals to field generating devices disposed with respect to the stem cells so as to facilitate the treatment of diseased or injured bone and other tissues. The resulting methods and devices are useful for the targeted treatment of osteoporosis, osteopenia, osteonecrosis, fresh bone fractures, fractures at risk, nonunion, bone defects, spine fusion, and/or other conditions in which BMP 2 and 4, TGF-beta 1, 2, and 3, FGF-2, osteocalcin, and alkaline phosphatase mRNA and/or protein deficiencies in stem cells has been implicated.

The invention belongs to the technical field of biological engineering, and relates to a recombinant chicken osteocalcin maturation protein monoclonal antibody and application thereof. The recombinant chicken osteocalcin maturation protein monoclonal antibody is secreted by hybridoma cell 3H4 with the preservation number of CGMCC No.4502. The preservation number of the hybridoma cell 3H4 which ispreserved in the china general microbiological culture collection center at December 23rd, 2010 is China general microbiological culture collection (CGMCC) No. 4502. The hybridoma cell system 3H4 canstably secrete the recombinant chicken osteocalcin maturation protein monoclonal antibody, wherein the antibody is good in specificity and can be combined with the specificity of the chicken osteocalcin protein to assay the chicken osteocalcin protein. The chicken osteocalcin assay reagent prepared by the antibody and particularly the chicken osteocalcin enzyme-linked immuno sorbent assay (ELISA)kit can be used for assaying the content of the chicken serum osteocalcin, thereby being good for monitoring the bone growth condition, preparing the reagent for diagnosing the chicken bone disease, and diagnosing the other diseases which can cause the abnormal change of the BGP.

The invention relates to novel application of taurochenodeoxycholic, and particularly relates to novel application of the taurochenodeoxycholic acid in treating adverse reactions of glucocorticoid medicaments. Through studying on the taurochenodeoxycholic acid, the inventor discovers that the taurochenodeoxycholic acid can resist apoptosis of suprarenal gland cells and promote multiplication of adrenal cortex stem cells so as to recover the hypothalamic-pituitary-adrenal axis inhibition caused by the glucocorticoid medicaments, promotes osteoblast to secrete osteocalcin and improve the reduced bone mineral density so as to recover osteoporosis caused by the glucocorticoid medicaments, and can reinforce the mucosal immunity function and promote multiplication of small intestine stem cells; therefore, the taurochenodeoxycholic acid can be directly administrated or made into various preparations or mixtures for preventing and treating adverse reactions caused by the glucocorticoid medicaments.

The invention provides a kit for detecting osteocalcin. The kit is high in detecting sensitivity and good in reliability. The kit for detecting the osteocalcin is characterized in that the kit comprises a calibration product, a quality control product, a biotin-labeled osteocalcin antibody solution, a horseradish peroxidase-labeled osteocalcin antibody solution, a streptavidin-labeled nano magnetic particle suspension and a substrate solution; the calibration product comprises an osteocalcin antigen solution with the concentration being 0 ng/mL, 10 ng/mL, 25 ng/mL, 50 ng/mL, 75 ng/mL and 250 ng/mL; the concentration of the biotin-labeled osteocalcin antibody solution is 1.0 [mu]g/mL; the concentration of the streptavidin-labeled nano magnetic particle suspension is 0.5 mg/mL; and the concentration of the horseradish peroxidase-labeled osteocalcin antibody solution is 1.0 [mu]g/mL.

A process for producing an extract containing activated osteocalcin; an extract which can be obtained by this production process; a food, a drink, a drug, an oral cavity-care composition and a feed containing this extract; and a growth enhancer containing osteocalcin originating in a bone.

The invention discloses a kangaroo bone extract and an extraction method thereof, wherein the extraction method comprises: taking kangaroo bone, cleaning, grinding, carrying out acid digestion to demineralize, adopting a protein extraction solution to further carry out multiple digestions, adopting organic solvent leaching to remove impurities, and drying to obtain kangaroo bone extract protein particles. With the extraction method, per g of the protein particles contains 9.5-10.7 mg of protein, 4.8-6.13 mg of osteocalcin, and 4.35*10<-3> ng of bone morphogenetic protein; and mixtures of more than 500 proteins can be extracted from the kangaroo bone, wherein the proteins comprise osteocalcin, osteonectin, bone morphogenetic protein, alkaline phosphatase, insulin-like growth factor and the like, wherein more than 30 proteins are related to bone metabolism, provide ideal promotion effects for induction of differentiation of mesenchymal stem cells into bone cells and cartilage cells, and can be used for preventing and treating bone joint diseases such as osteoporosis and the like. In addition, the kangaroo bone extract protein particles obtained by using the extraction method contain a lot of proteins and related effective components, an extraction effect is good, the kangaroo bone extract protein particles can be used as base raw materials of health products and drugs for prevention and treatment of bone joint diseases, and qualities and effects of kangaroo products are increased.

Provided is a method of mineralizing tissue, including placing within a body of a subject a substance, wherein the substance includes osteopontin and osteocalcin. Also provided is a tissue mineralization-promoting substance including osteopontin and osteocalcin, and an article for promoting tissue mineralization, including an implant which may be an orthopedic implant or an endosseous implant, and a substance disposed on a surface of the implant including osteopontin, and osteocalcin. A method of making a tissue mineralization-promoting substance, including combining osteopontin and osteocalcin, is also provided. Other features, including calcium phosphate, type-I collagen, mesenchymal stem cells, and growth factors, are also provided.

The loss of the SOST gene product sclerostin leads to sclerosteosis characterized byihigh bone mass (HBM). In this report, we found that sclerostin could antagonize canonical, Wnt signaling in human embryonic kidney A293 cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by over-expression of Wnt coreceptor LRP5. In addition, we found that sclerostin bound to LRP5 as well as LRP6 and identified the first two YWTD-EGF repeat domains of LRP5 as being responsible for the binding. Although these two repeat domains are required for transducing canonical Wnt signals, canonical Wnt did not appear to compete with sclerostin for binding to LRP5. Examination of the expression of sclerostin and Wnt7b, an autocrine canonical Wnt, during primary calvarial osteoblast differentiation revealed that sclerostin is expressed at the late stages of osteoblast differentiation coinciding with the expression of osteogenic marker osteocalcin and trailing after the expression of Wnt7b. Given the plethora of evidence indicating that canonical Wnt signaling stimulates osteogenesis, we believe that the HBM phenotype associated with the loss of sclerostin may at least in part be attributed to an increase in canonical Wnt signaling resulting from the reduction in sclerostin-mediated Wnt antagonism.

Blood displacement foundation liquid comprises calcium ions and citron acid radicals, wherein according to the content in each liter of injection water, citron acid radicals are 5 to 15 mmol and calcium ions are 1.2 to 1.8 mmol. The invention further provides a preparation method of the blood displacement foundation liquid. The blood displacement foundation liquid is provided with the calcium ions based on existing citric acid anticoagulation displacement liquid. Even though the added calcium ions complexes a part of the citron acid radicals, the blood displacement foundation liquid is enabled to have good anticoagulation effects by adjusting adding amount of the calcium ions and effectively prevent hypocalcemia. Calcium ions are not required to be inputted additionally from peripheral veins so as to save clinical operation steps. Simultaneously, the blood displacement foundation liquid can guarantee stability of the level of blood serum osteocalcin of patients, thereby avoiding remarkable large fluctuation of the level of the blood serum osteocalcin and reducing clinical risks.

The invention discloses an application of nattokinase to a medicine for treating osteoporosis. The nattokinase is prepared by fermenting a nattokinase strain; the nattokinase used as an active component is applied to the medicine for treating osteoporosis alone or in combination with other medicines. The nattokinase has very good effects of reducing the s-TRAP value, increasing the bone mineral content, increasing mineral density and increasing calcitonin (CT), bone gla protein (BGP) and estradiol (E2), and the nattokinase can be found to have the remarkable effect of improving osteoporosis.

The invention discloses a kit for measuring the content of osteocalcin, and a detection method thereof. The kit comprises a magnetic particle coupled N-MID capture antibody, an enzyme labeled N-MID detection antibody, an N-MID calibration product, a chemiluminescence substrate of enzyme action, and cleaning fluid; a whole segment of osteocalcin is generally detected by using euzymelinked immunosorbent assay and radioimmunoassay at home, since the own stability of the osteocalcin is poor, the specimen storage temperature and time will affect the experimental result, N-mid-end osteocalcin (N-MID) is not easily hydrolyzed by protease, so that the content in the serum is stable, the kit disclosed by the invention is used for detecting the N-MID in the serum, and the detection result is reliable.

The invention relates to a health product for old people with effects for supplementing calcium, and regulating blood lipid and blood pressure. The product comprises the following main raw materials in percentages by weight: 8-12% of propolis liquid, 3-5% of Dendrobium officinale, 1-2% of osteocalcin, 4-7% of sea cucumber, 0.2-0.5% of ginseng, 1-3% of Saussurea involucrate, 0.005-0.01% of cordyceps, 2-5% of Chinese wolfberry fruits, 1-3% of ganoderma, 2-5% of 60-year-old poria cocos, 3-5% of cistanche, 1-5% of agar, and 0.1-0.3% of sodium benzoate. The raw materials of the product are almost traditional Chinese medicines, in order to accord with original intention of health products, and realize main purposes for conditioning body and enhancing immunization.

The invention discloses an osteocalcin slow-release microsphere preparation for injection, which comprises osteocalcin, zinc sulfate and lactic acid-glycolic acid copolymer, wherein the weight ratio of the osteocalcin to the zinc sulfate to the lactic acid-glycolic acid copolymer is (5-30):(0.1-1):100. The preparation method of the osteocalcin slow-release microsphere preparation for injection comprises the following steps: 1) dissolving the osteocalcin and the zinc sulfate in water, and using as an in-water phase; 2) dissolving lactic acid-glycolic acid copolymer in dichloromethane, and using as an oil phase; 3) mixing the in-water phase and the oil phase, and stirring to obtain a primary emulsion; 4) adding the primary emulsion into a polyvinyl alcohol water solution while stirring, thus obtaining a compound emulsion; and 5) stirring the compound emulsion at room temperature for 5 hours, centrifuging, collecting microspheres, washing the microspheres with water for injection, and carrying out freeze-drying. The preparation disclosed by the invention has good stability, high drug-loading rate and high in-vivo safety, the envelopment rate can be controlled at 82-95%, and the preparation can not be subjected to degradation, aggregation and conformational change under accelerated test conditions. The tail intravenous injection to mice shows that the bioavailability of the slow-release microsphere preparation for injection can be up to 72-76%.

The invention discloses a Rochel reverse-transcription reagent and a preparation method thereof, and specifically relates to the field of cell biotechnology. The Rochel reverse-transcription reagent comprises deionized water, EASY Dilution for Real Time PCR, gDNA Eraser, 5x gDNA Eraser Buffer, RNase inhibitor and gene primers; and the gene primers comprise telomerase reverse transcriptase, acid-glyceraldehyde dehydrogenase, alkaline phosphatase, core-binding factor, bone sialoprotein, osteocalcin, osteopontin and type-I collagen. Through arrangement of a plurality of combinatorial gene primers, the Rochel reverse-transcription reagent is capable of facilitating osteocyte reproduction; and fast reverse transcription is ensured during application. Moreover, high survival rate and good growthrate are achieved so as to facilitate study on periodontal membrane regeneration. In the process of production, aseptic treatment and low-temperature storage are adopted, so that, the the reverse-transcription reagent is good in quality and long in storage life; and thus, needs of DNA biosynthesis can be satisfied.